Clinical characteristics of influenza virus-induced lower respiratory infection during the 2015 to 2016 season.
PMID: 29433792
2018
Journal of infection and chemotherapy
Abstract: In the six PB cases, we found one patient with H275Y mutation in neuraminidase.
Result: The sequence data for the NA gene revealed that patient 2 was infected with the oseltamivir-resistant H275Y mutant virus from the specimen taken before the treatment of neuraminidase inhibitor.
Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
PMID: 29866491
2018
Journal of infection and chemotherapy
Abstract: The most common neuraminidase (NA) amino acid substitution was H275Y in A (H1N1)pdm09 virus, which confers HRI by oseltamivir.
Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus.
Abstract: Combination of H275Y with an I223V or S247N mutation results in extreme impairment of oseltamivir's inhibition potency.
Abstract: In contrast, the major oseltamivir resistance mutation H275Y causes a significant decrease in the enzyme's ability to bind this drug.
Abstract: Our crystal structures also helped explain the augmenting effect on resistance of combining H275Y with both substitutions.
Abstract: Our structural analyses revealed that the H275Y substitution has a major effect on the oseltamivir binding pose within the active site while the influence of other studied mutations is much less prominent.
Abstract: The resistance substitutions I223V and S247N, alone or in comb
Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance.
Abstract: No H275Y mutation was reported from A/H1N1 positives.
Abstract: Testing for H275Y mutation was done to determine sensitivity to oseltamivir.
Result: No H275Y mutation on neuraminidase was reported from pandemic H1N1 positives, hence viruses remained susceptible to oseltamivir.
Discussion: Another important observation in our study was the absence of the H275Y mutation on neuraminidase in our isolates which suggested that the isolates were susceptible to oseltamivir.
Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.
PMID: 30201817
2018
Antimicrobial agents and chemotherapy
8Discussion: In the future, it is possible that the NA variants examined in our study may gain additional ""permissive"" mutations that improve their fitness, as was observed with the H275Y NA substitution in seasonal H1N1 viruses."
Introduction: The H273Y NA substitution in influenza B viruses occurs at the equivalent residue to that of the H275Y NA substitution in influenza A(H1N1) viruses, which was present in the oseltamivir-resistant influenza A(H1N1) viruses that spread globally in 2008/2009.
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.
Result: The influenza A(H1N1)pdm09-NA/H275Y, A(H3N2)-NA/E119V or -NA/R292K, and influenza B-NA/D197E mutant viruses exhibited HRI or RI against at least one of the four NA inhibitors, whereas no significant d
Table: H275Y
Discussion: In the case of oseltamivir- and peramivir-resistant A(H1N1) and A(H1N1)pdm09 viruses with an NA H275Y substitution, some amino acid substitutions in the NA protein were able to compensate for the detrimental effect of the H275Y substitution on viral fitness.
Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells.
Introduction: Although the detection rate of NA inhibitor resistance was initially low (~1% of A(H1N1)pdm09 viruses are resistant to oseltamivir), reports of increases in the prevalence of A(H1N1)pdm09 influenza viruses with the H275Y NA substitution (from >1.0 to 2.5%) in Japan in 20135, and isolation of community-transmitted, oseltamivir-resistant viruses suggest that this substitution is not deleterious to the fitness of
Method: Influenza A/Georgia/20/2006 (H1N1) H275Y (oseltamivir-resistant), A/Brisbane/59/2007 (H1N1), A/Tennessee/1-560/2009 (H1N1)pdm09, A/Perth/16/2009 (H3N2), A/Vietnam/1203/2004 (H5N1), A/Anhui/1/2003 (H7N9), and B/Texas/06/2011 viruses were obtained from the Influenza Division at the Centers for Disease Control and Prevention, and St Jude Children's Research Hospital.
Table: H275Y
Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Result: However, the chromatogram of the NA genes from three mice treated with the combination and positive for H275Y by ddPCR showed a mixed population at this codon.
Result: Interestingly, RT-ddPCR assay demonstrated that the group treated with oseltamivir-favipiravir combination had higher % of H275Y mutant population than that of mice treated with oseltamivir monotherapy on days 8 and 12 p.
Result: and, on day 15 p.i., three mice out of four had 16.4, 6.5 and 1.7% of H275Y variant (Table 2).
Result: but, on day 15 p.i., they showed higher proportion of H275Y variant with three mice having 19.1, 16.91 and 26.24% of H275Y variant (Table 1).
Result: did not show the presence of the H275Y in mice treated with oseltamivir.
Antiviral resistance markers in influenza virus sequences in Mexico, 2000-2017.
IV mutation literature information.
PMID: 
2018
Journal of infection and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT